Table 3.

Potential drugs targeting ADAM proteases.

	Cancer type	ADAM	Drugs	Biomarker	Ref
1	HCC	ADAM9(mRNA,protein)	sorafenib	MICA	[112] Kohga K et al.
2	HCC	ADAM9,ADAM10(mRNA,protein)	regorafenib	MICA	[76] Arai J et al.
3	HCC	ADAM9(enzyme)	LTRAs	MICA	[78] Arai J et al.
4	HCC	ADAM9(enzyme)	retinoids	MICA	[79] Otoyama Y et al.
5	HCC	ADAM10(mRNA)	epirubicin	MICA	[113] Kohga K et al.
6	HCC	ADAM10(enzyme)	disulfiram	MICA	[114] Goto K et al.
7	HCC	ADAM17(enzyme)	lomofungin	MICA, MICB, ICAM-1	[22] Arai J et al.
8	CRC	None	regorafenib	MICA	[23] Arai J et al.

Potential drugs targeting ADAM proteases in two approaches with gastroenterological cancers, (1) reduction of ADAM expression in transcriptionally and translationally and (2) inhibition of ADAM enzymatic activity, are shown.

LTRAs leukotriene receptor antagonists.